IP Library Patent Application 15915765
Patent Application
App. No. 15/915,765

Specific Targeting of RNA Expanded Repeat Sequences

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/915,765
Abstract

The present invention provides small molecule compounds that can form covalent adducts with specific sequences of RNA, such as the hairpin loop r(CUG) exp sequence which is a cause of myotonic dystrophy type 1 (DM1), or the r(CGG) exp sequence which is a cause of fragile X-associated tremor/ataxia syndrome (FXTAS); to methods of making the small molecule compounds; and to methods of using the small molecular compounds in the treatment of DM1 or of FXTAS in patients afflicted therewith. The invention further provides a method for identifying an RNA target of a small molecule drug in vivo, using a small molecule drug conjugated to an RNA-reactive crosslinker group and a reporter group, contacting a cell or nucleic acid extract with the small molecule drug conjugate, then separating RNA targets crosslinked to the small molecule drug conjugate by interaction of the affinity group with a complementary affinity group.

Claims (43)

1 . A compound of formula (I)

wherein

each individually selected R or R′ is H or (C1-C6)alkyl;

n1 is 2, 3, 4, 5, or 6;

Z is a (C1-C3)alkylene group, optionally substituted with a reporter or affinity group;

L is a linker group comprising an optionally substituted (C1-C6)alkylene, wherein one or two carbon atoms is optionally replaced by O;

XL is an RNA-reactive crosslinking group;

each individually selected Ht is a group of formula

wherein

n2 is 0, 1, 2, or 3;

n3 is 0, 1, 2, or 3;

Y is O or CH 2 ;

a wavy line indicates a point of bonding;

or any tautomer thereof; or any salt thereof, or any stereoisomer thereof.

2 . The compound of claim 1 wherein the crosslinking group is an alkylating group.

3 . The compound of claim 2 wherein the alkylating group is a chlorambucil derivative.

4 . The compound of claim 1 wherein the crosslinking group is a triggered crosslinker using photochemical or shape-triggered catalysis.

5 . The compound of claim 1 wherein the compound is of formula

or is of formula

wherein Ht, R, and R′, are as defined in claim 1 ;

or any tautomer thereof; or any salt thereof, or any stereoisomer thereof.

6 . The compound of claim 1 wherein Ht is

wherein a wavy line indicates a point of bonding;

R is n-propyl; R′ is H; or any combination thereof;

or any tautomer thereof; or any salt thereof, or any stereoisomer thereof.

7 . The compound of claim 1 wherein the compound is 2H-4-CA of formula

or is compound 2H-5-CA of formula

wherein Ht is a group of formula

wherein a wavy line indicates a point of bonding;

or any tautomer thereof; or any salt thereof, or any stereoisomer thereof.

8 . The compound of claim 1 wherein Z is an unsubstituted alkylene group.

9 . The compound of claim 1 wherein Z is an alkylene group substituted with an affinity group.

10 . The compound of claim 9 wherein the affinity group is a biotin-comprising moiety.

11 . The compound of claim 10 , wherein the compound is

wherein Ht, R, R′, n1, L, and XL, are as defined in claim 1 ;

or any tautomer thereof; or any salt thereof, or any stereoisomer thereof.

12 . The compound of claim 11 , wherein n1 is 4 or 5.

13 . The compound of claim 12 , wherein the compound is 2H-4-CA-biotin of formula

or is 2H-5-CA-biotin of formula

or any tautomer thereof; or any salt thereof, or any stereoisomer thereof.

14 . A covalently-linked complex of the compound of formula (I) of claim 1 and a segment of RNA comprising a hairpin loop.

15 . The complex of claim 14 wherein the RNA comprises an r(CUG) exp segment.

16 . The complex of claim 14 wherein the RNA comprises an r(CGG) exp segment.